Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.39 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | USP19 | O94966 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078572 | 0.87 | MGLL (0.43) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL6079188 | 0.83 | ITGB3 (0.44) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL7262998 | 0.80 | TGM2 (0.42) | ENPP2ATXN2 | |
| SCHEMBL6079546 | 0.80 | SMN1; SMN2 (0.41) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL7257427 | 0.79 | GRIN2B (0.37) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL7257549 | 0.78 | TSHR (0.43) | MEN1KMT2AGAACYP2C19ALDH1A1 | |
| SCHEMBL1666825 | 0.75 | MEN1 (0.53) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL6079116 | 0.74 | MEN1 (0.42) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL26090713 | 0.73 | SMN1; SMN2 (0.47) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL13395027 | 0.73 | MEN1 (0.56) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122662-B2 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20050148769-A1 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| US-6858599-B2 | Inhibitor for activated blood coagulation factor X | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-22 | — | — | US | disclosed |
| EP-1191028-B1 | TRICYCLIC COMPOUNDS HAVING SPIRO UNION | MOCHIDA PHARM CO LTD (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1346994-A1 | CHOLESTEROL BIOSYNTHESIS INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT TRICYCLIC SPIRO COMPOUNDS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-20030045520-A1 | Tricyclic compound having spiro union | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | US | disclosed |
| EP-1191028-A1 | TRICYCLIC COMPOUNDS HAVING SPIRO UNION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | VKORC1, CYP46A1, TFPI | MEN1 1423/4885KMT2A 2943/4885NPSR1 2510/4885 |
| US-20030045520-A1 | Tricyclic compound having spiro union | F2, TFPI, F11 | MEN1 631/4885KMT2A 3390/4885NPSR1 2064/4885 |
| US-20050148769-A1 | Tricyclic compound having spiro union | TFPI, F2, F12 | MEN1 699/4885KMT2A 3342/4885NPSR1 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.